Mundipharma launches Remsima®, a new-generation value-based monoclonal antibody

• The European Medicines Agency has determined that Remsima, a biosimilar, is comparable to the reference product Remicade® in terms of safety, efficacy and quality across all approved indications • Remsima is expected to cost less than the reference product; these savings could allow more patients with inflammatory autoimmune diseases to access monoclonal antibody therapy • Biosimilar monoclonal antibodies are expected to save European healthcare systems between €1.8 and €20.4 billion between 2007 and 2020 (1)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Biosimilars Practical therapeutics Cost effectiveness Industry News mAbs Legislation & regulation Gastroenterology Patient care efficacy inflammatory autoimmune diseases Latest News reference product remicad Source Type: news